Organisation paid for research Program year 2025 Source: CMS Open Payments

WVU Research Corporation

Neither a doctor nor a teaching hospital

Research payments

$262,040

56 payments

Through program year 2025, WVU Research Corporation is reported as receiving $262,040 in research payments, across 56 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $16,337 10
2024 Research $7,083 3
2023 Research $3,568 2
2022 Research $22,237 7
2021 Research $144,238 3
2020 Research $22,490 14
2019 Research $46,087 17

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pacira Pharmaceuticals Incorporated $156,204 5 payments
  2. Ge Healthcare $40,632 14 payments
  3. Pharmacyclics LLC, An AbbVie Company $15,673 11 payments
  4. AbbVie, Inc. $15,020 9 payments
  5. Shire North American Group Inc $13,000 3 payments
  6. W. L. Gore & Associates, Inc. $7,200 2 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $6,245 7 payments
  8. TESARO, Inc. $4,250 1 payment
  9. Celgene Corporation $2,000 1 payment
  10. Orthofix Medical, Inc. $1,200 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of Exparel When Administered Via Infiltration Into the Transversus Abdominis Plane Versus Standard of Care in Subjects Undergoing Elective Cesarean Section $144,204 2 payments
  2. A Phase 3 Open Label Multicentre Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease $25,371 7 payments
  3. Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma $15,020 9 payments
  4. A Phase 2B, Multicenter, Randomized, Open-Label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of Shp607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compared to Standard Neonatal Care in Extremely Premature Infants $13,000 3 payments
  5. A Phase 3| Open Label| Multicenter Study of Flurpiridaz (18F) Injection for Positive Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease $10,982 2 payments
  6. A Multicenter, Randomized, Controlled, Phase 4, Pragmatic Study of Multimodal Analgesia Using Local Infiltration With A Single-Dose of Exparel VS. Usual Care for Postsurgical Analgesia After Posterior Lumbar Spine Fusion Surgery $10,700 1 payment
  7. Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma $9,366 4 payments
  8. Evaluation of the GORE Ascending Stent Graft in the Treatment of Isolated Lesions, Pseudoaneurysms, and Penetrating Aortic Ulcers of Ascending Aorta and Aortic Arch $7,200 2 payments
  9. A Phase 1 Dose Escalation and Cohort Expansion Study of Tsr-042, An Anti-Pd-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors $4,250 1 payment
  10. A Phase 3| Open Label| Multicenter Study of Flurpiridaz (18F) Injection for Positive Emission Tomography (PET) Imaging $4,245 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record